Because the disease burden is huge: Rising obesity Increasing Type 2 Diabetes High cardiovascular risk These drugs address all three which is why demand is exploding worldwide
But taken in large amounts, without enough hydration, it can overwhelm the digestive system
10mg vial at 100mcg/dose (starting) = 100 doses 10mg vial at 250mcg/dose (standard) = 40 doses 10mg vial at 500mcg/dose (higher end) = 20 doses At 250mcg daily, a 10mg vial would theoretically last 40 days but since reconstituted peptide should be used within 28 days, plan to start a new vial after 4 weeks regardless of remaining volume
GLP-1 Medications with a simple generic name of "semaglutide", "liraglutide", "tirzepatide", "dulaglutide", "exenatide", "exenatide microspheres", or "insulin degludec/liraglutide" and at least one of: A pharmaceutical class of "ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEP AGONIST" or "ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION" A pharmaceutical class that contains "GLP-1" A pharmaceutical subclass that contains the text "GLP-1"
Research attention centers on its relationship to collagen production , glycosaminoglycan deposition , and the enzymatic turnover that governs tissue remodeling
These were used to plot concentration-response curves, which were analysed using a three-parameter logistic equation